Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
-
ACADEMIA Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
-
REGULATORY Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
-
COMMENTARY LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
October 19, 2021
-
BUSINESS Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
-
BUSINESS Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
-
COMMENTARY Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
-
ORGANIZATION Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
-
ORGANIZATION EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
-
COMMENTARY Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
-
BUSINESS Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
-
REGULATORY Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
-
BUSINESS Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
-
BUSINESS Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
-
REGULATORY MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
-
REGULATORY Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
-
REGULATORY Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
-
BUSINESS Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
-
ORGANIZATION JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
-
BUSINESS Takeda Suspends PII Trials of Narcolepsy Drug Hopeful on Safety Concerns
October 7, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…